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Abstract: Probiotics are linked to positive regulatory effects on the immune system. The aim of the
study was to examine the association between the exposure of probiotics via dietary supplements or
via infant formula by the age of 1 year and the development of celiac disease autoimmunity (CDA)
and celiac disease among a cohort of 6520 genetically susceptible children. Use of probiotics during
the first year of life was reported by 1460 children. Time-to-event analysis was used to examine the
associations. Overall exposure of probiotics during the first year of life was not associated with either
CDA (n = 1212) (HR 1.15; 95%CI 0.99, 1.35; p = 0.07) or celiac disease (n = 455) (HR 1.11; 95%CI
0.86, 1.43; p = 0.43) when adjusting for known risk factors. Intake of probiotic dietary supplements,
however, was associated with a slightly increased risk of CDA (HR 1.18; 95%CI 1.00, 1.40; p = 0.043)
compared to children who did not get probiotics. It was concluded that the overall exposure of
probiotics during the first year of life was not associated with CDA or celiac disease in children at
genetic risk.
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1. Introduction
Probiotics have been defined as live organisms which confer a health benefit to the host when
administered in adequate amounts [1]. There is a long history of safe use of selected microbes in foods,
but the vulnerability of certain immunocompromised populations should be taken into consideration
before probiotic supplementation [2]. Administration of probiotics to healthy infants is considered
to be safe [3,4] and is assumed to have a positive effect on the regulation of the immune system.
Probiotic supplementation has long been used for its preventive effects, e.g., on atopic eczema [5,6]
and to improve and maintain gastrointestinal health [7]. Whether probiotics are beneficial against
colic pain and decrease the related crying time in young infants remains a controversial topic [8–11].
Nevertheless, supplementation of infant diets with probiotics has become more common worldwide
during the recent years. For instance, a considerable increase in probiotic supplement use has been
observed in Sweden since 2004 [12,13], while infants in Finland have been commonly given probiotics
since the late 1990s [14]. Despite the increase in probiotic use, their mechanisms of action have not
entirely been established. Furthermore, it has been suggested that dead bacteria and their components
can also exhibit probiotic properties, in addition to probiotics and probiotic metabolites [15].
Celiac disease is a chronic autoimmune disease of the small bowel, characterized by villous
atrophy and inflammation of the intestinal mucosa [16]. Early infant feeding, with emphasis on gluten
intake, influences risk [17]. While gluten is the necessary antigen for celiac disease to develop, there
is some evidence that various environmental exposures such as repeated gastrointestinal infections
may also trigger the disease [18–20], either on their own or in interaction with gluten exposure [21].
Certain changes in gut microbiota composition, as well as the development and maturity level of the
gut microbiota, have been linked to celiac disease [21,22]. Some previous studies have also shown that
probiotics are beneficial for children who suffer from this autoimmune disorder [23,24].
We previously demonstrated that early exposure of probiotics may decrease the risk of type
1 diabetes (T1D) related autoimmunity among at-risk children in the ongoing prospective, The
Environmental Determinants of the Diabetes in the Young (TEDDY) birth cohort study [12] which is a
multi-national longitudinal observational study with the goal of identifying environmental factors
associated with T1D and celiac disease. To date there is no prospective study showing that probiotics
may prevent celiac disease. The aim of this study was to examine whether the timing of initial probiotic
exposure during the first year of life is associated with the risk of celiac disease autoimmunity (CDA)
and celiac disease in the TEDDY study.
2. Materials and Methods
2.1. Study Population
The TEDDY study involves 6 clinical research centers located in Colorado, Georgia, and Washington
in the U.S. and in Finland, Germany, and Sweden in Europe. All sites follow the same study protocol
including scheduled visits every 3rd month until the age of 4 years and every 6th month thereafter
until 15 years of age [25]. Between September 2004 and February 2010, the TEDDY study screened
424,788 newborns infants of whom 21,589 infants fulfilled the inclusion criteria based on the Human
Leukocyte Antigen (HLA) genotyping (Supplemental Table S1). Among those eligible children, 8676
children were enrolled in the prospective cohort study. For this study we only included children
with selected HLA genotypes: DR3/3, DR3/4, DR4/4, and DR4/8 who had been screened for tissue
transglutaminase autoantibodies (tTGA) (n = 6520) (Figure S1). As of July 2017, 6520 children had been
followed to a median (interquartile range (IQR)) age of 8.7 (7.4–10.2) years and included for this study.
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For all study participants, separate written informed consent for genetic screening and participation
in the follow-up study were obtained from a parent or primary caregiver before they participated in the
study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by local Ethics Committees and Institutional Review Boards and monitored by an External
Evaluation Committee formed by the National Institutes of Health.
2.2. Screening for Celiac Disease Related Autoimmunity (CDA) and Celiac Disease
Annual screening for celiac disease starts with tTGA at 2 years of age, as previously described [26].
Children who are tTGA positive are re-tested after 3–6 months and defined as having CDA if persistently
tTGA positive in two consecutive samples. In addition, children who tested tTGA positive had their
serum samples retrospectively analyzed. Samples from as early as 3 months of age were available in
order to determine the closest time-point of seroconversion. Caregivers to children with CDA were
referred to their health care provider for further evaluation of celiac disease. For the purpose of this
study, celiac disease was defined as biopsy proven (i.e., an intestinal biopsy showing a Marsh score ≥ 2)
or having a persistently tTGA level of ≥100 units if a biopsy was not performed [27].
2.3. Information on Characteristics, Diet and Health of the Study Population
Information about basic demographic characteristics of the mother and her newborn baby was
received from the infant screening form. A questionnaire was mailed to the home of the mother
prior to the first clinic visit (3 to 4.5 months postpartum). This questionnaire contained questions
regarding illnesses during pregnancy, mother’s use of medications and dietary supplements, smoking
status, and maternal body mass index (BMI) before pregnancy. After enrollment, families received a
questionnaire on the mode of delivery and the child’s early diet, including use of probiotics between 0
to 3 months of age. Information about the mother’s education and the birth order of the child was
received from the primary caretaker questionnaire at the 9-month clinic visit. Parents were advised to
consistently maintain a diary after the first clinic visit in order to collect information on child illnesses
and diet. The child’s age at the start and end of probiotic supplementation and/or infant formula, as
well as of each type of formula, were recorded. Probiotic exposure was defined as the timing of first
probiotic introduction of either via dietary supplement or infant formula. Species of probiotics in
supplements and infant formulas were examined based on the composition of the self- reported brand
name products. The majority of the probiotic bacteria in dietary supplements and infant formulas
taken by the TEDDY children consisted of Lactobacillus reuteri and Lactobacillus rhamnosus, although
17% of the families were not able to identify the brand name of the probiotics they used. The latter was
more likely to occur during the first 3 months of age, when the information on probiotic intake was
recalled retrospectively. Study nurses reviewed the questionnaires and diaries during the family’s
clinic visit or over the phone every 3 months to minimize missing or inaccurate information.
2.4. Statistical Methods
Time-to-event analysis with Cox proportional hazards (PH) modeling was performed to examine
the overall probiotic exposure and timing in the first year of life in relation to the risk of CDA and
celiac disease. The magnitudes of the associations were described by hazard ratios (HR) with 95%
confidence intervals (CI). The Cox PH models were adjusted for known risk factors for celiac disease
including sex, HLA genotype, family history of celiac disease (first-degree relative (FDR) with celiac
disease vs. not), and country (as strata). In addition, Cox PH models were adjusted for potential
confounders associated with both probiotics use and CDA or celiac disease, including birth year, mode
of delivery, mother’s education, duration of exclusive breastfeeding, and child’s diarrhea status in the
first 3 months.
Probiotic exposure in the first year of life was incorporated into the Cox PH model in two ways:
(a) probiotic exposure was categorized as binary (yes vs. no): probiotics users vs. non-users, and (b)
source of probiotic exposure was categorized into three groups: dietary supplements, infant formula,
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or none. Among probiotics users, the age at first probiotic exposure was examined as a continuous
variable in the Cox PH model. Analyses were carried out using the Statistical Analysis System software
(version 9.4; SAS Institute, Cary, NC, USA).
3. Results
3.1. Study Population
During follow-up, 1212 (18.6%) children were identified as having CDA at a median (IQR) age of
3.3 (2.2–5.0) years (range 0.9–11.5 years), while 455 (7.0%) children were diagnosed with celiac disease
at a median (IQR) age of 4.3 (3.2–6.2) years (range 1.2–12.5 years). The characteristics of the children by
the status of CDA or celiac disease are presented in Table 1.
Table 1. Characteristics of the study participants by status of celiac disease autoimmunity (CDA) and
of celiac disease.
Developed CDA
(n = 1212)
Did not Develop
CDA (n = 5308)
Developed Celiac
Disease (n = 455)
Did not Develop Celiac
Disease (n = 6065)
Country
-US 437 (36.1) 2195 (41.4) 135 (29.7) 2497 (41.2)
-Finland 257 (21.2) 1227 (23.1) 85 (18.7) 1399 (23.1)
-Germany 58 (4.8) 289 (5.4) 17 (3.7) 330 (5.4)
-Sweden 460 (37.9) 1597 (30.1) 218 (47.9) 1839 (30.3)
Family member with
celiac disease 123 (10.1) 136 (2.6) 76 (16.7) 183 (3.0)
Sex, male 517 (42.7) 2815 (53.0) 167 (36.7) 3165 (52.2)
HLA DR-DQ genotype
-DR4-DQ8/DR4-DQ8 230 (19.0) 2235 (42.1) 73 (16.0) 2392 (39.5)
-DR3-DQ2/DR4-DQ8 477 (39.4) 2176 (41.0) 153 (33.7) 2500 (41.2)
-DR3-DQ2/DR3-DQ2 505 (41.6) 897 (16.9) 229 (50.3) 1173 (19.3)
Birth year
2004–5 217 (17.9) 856 (16.1) 105 (23.0) 968 (16.0)
2006 243 (20.0) 887 (16.7) 76 (16.7) 1054 (17.4)
2007 244 (20.1) 1141 (21.5) 90 (19.8) 1295 (21.3)
2008 220 (18.2) 1104 (20.8) 80 (17.6) 1244 (20.5)
2009–10 288 (23.8) 1320 (24.9) 104 (22.9) 1504 (24.8)
Mode of delivery—
Cesarean section
Yes 262 (21.6) 1394 (26.3) 85 (18.7) 1571 (25.9)
No 950 (78.4) 3910 (73.7) 370 (81.3) 4490 (74.1)
Mother’s education
—more than high school 1016 (85.2) 4203 (81.5) 368 (82.5) 4851 (82.1)
Duration of exclusive
breastfeeding at least
3 months
363 (30.0) 1275 (24.0) 143 (31.4) 1495 (24.7)
Exposure to probiotics
by the age of 12 months 281 (23.2) 1179 (22.2) 99 (21.8) 1361 (22.4)
Source of first exposure
to probiotics by the age
of 12 months
-Dietary supplement 238 (19.6) 949 (17.9) 83 (18.3) 1104 (18.2)
-Infant formula 42 (3.5) 228 (4.3) 16 (3.5) 254 (4.2)
-Both 1 (0.1) 2 (0.0) 0 (0.0) 3 (0.0)
Age (weeks) at first
probiotic exposure
among probiotics users
median (Q1–Q3) 5 (2, 26) 6 (2, 19) 5 (3, 26) 6 (2, 20)
mean (SD) 13.4 (14.7) 12.1 (13.2) 14.5 (15.3) 12.2 (13.3)
Nutrients 2019, 11, 1790 5 of 14
Table 1. Cont.
Developed CDA
(n = 1212)
Did not Develop
CDA (n = 5308)
Developed Celiac
Disease (n = 455)
Did not Develop Celiac
Disease (n = 6065)
Age (weeks) at first
probiotic exposure
among probiotics users
with first exposure from
dietary supplements
median (Q1–Q3) 4 (2, 20) 5 (3, 17) 4 (2, 26) 5 (2, 17)
mean (SD) 12.5 (14.5) 11.8 (13.3) 13.6 (15.4) 11.8 (13.4)
Age (weeks) at first
probiotic exposure
among probiotics users
with first exposure from
infant formula
median (Q1–Q3) 20 (4, 28) 9 (2, 24) 22 (4, 26) 10 (2, 24)
mean (SD) 19.0 (14.9) 13.4 (12.6) 19.0 (14.4) 14.0 (13.0)
Data are presented as number (percentage) unless otherwise indicated.
3.2. Probiotic Use
A total of 1460 children were exposed to probiotics via dietary supplements or infant formula
during the first year of life. The characteristics of the children by the source of probiotic exposure in the
first year of life are presented in Table 2. The participants’ characteristics that were positively associated
with probiotics use during the first year of life were country (p < 0.001), later birth year (p < 0.001), mode
of delivery (other than Cesarean section) (p = 0.012), being the first born child (p < 0.001), older maternal
age (p = 0.001), higher maternal education (p < 0.001), not smoking during pregnancy (p = 0.005),
maternal probiotic use during pregnancy (p < 0.001), shorter duration of exclusive breastfeeding
(p < 0.001), antibiotic use (p < 0.001), diarrhea during the first 3 months (p < 0.001), gastrointestinal
infections (p < 0.001), and lower incidence of common cold during the first 3 months (p = 0.006)
(Table 2). There was a considerable increase in probiotics use by birth year in Sweden (Figure S2) when
compared to other countries where there was not as much difference in the probiotics use across the
study years.
Table 2. Characteristics of probiotics users by source of first exposure and non-users during the first
year of life.
Source of First Probiotic Exposure
among Probiotics Users during the
First Year of Life a
Non-Users of
Probiotics (n = 5060) p
b p c
Dietary
Supplements
(n = 1187)
Infant Formula
(n = 270)
Country <0.001 <0.001
US 119 (10.0) 49 (18.1) 2464 (48.7)
Finland 776 (65.4) 29 (10.7) 678 (13.4)
Germany 10 (0.8) 154 (57.0) 182 (3.6)
Sweden 282 (23.8) 38 (14.1) 1736 (34.3)
Family member with
celiac disease 0.736 0.600
Yes 62 (5.2) 8 (3.0) 189 (3.7)
No 1125 (94.8) 262 (97.0) 4871 (96.3)
Sex 0.814 0.472
Male 614 (51.7) 133 (49.3) 2584 (51.1)
Female 573 (48.3) 137 (50.7) 2476 (48.9)
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Table 2. Cont.
Source of First Probiotic Exposure
among Probiotics Users during the
First Year of Life a
Non-Users of
Probiotics (n = 5060) p
b p c
Dietary
Supplements
(n = 1187)
Infant Formula
(n = 270)
HLA DR-DQ genotype 0.533 0.061
-DR4-DQ8/DR4-DQ8 519 (43.7) 83 (30.7) 1862 (36.8)
-DR3-DQ2/DR4-DQ8 446 (37.6) 137 (50.7) 2069 (40.9)
-DR3-DQ2/DR3-DQ2 222 (18.7) 50 (18.5) 1129 (22.3)
Birth year <0.001 <0.001
2004–5 97 (8.2) 45 (16.7) 930 (18.4)
2006 168 (14.2) 38 (14.1) 924 (18.3)
2007 260 (21.9) 47 (17.4) 1077 (21.3)
2008 272 (22.9) 64 (23.7) 988 (19.5)
2009–10 390 (32.9) 76 (28.1) 1141 (22.5)
Mode of delivery:
Cesarean section 0.012 0.281
Yes 238 (20.1) 99 (36.7) 1319 (26.1)
No 949 (79.9) 171 (63.3) 3737 (73.9)
Birth order, first child <0.001 0.314
Yes 575 (50.0) 131 (50.0) 2127 (43.4)
No 575 (50.0) 131 (50.0) 2778 (56.6)
Mother’s age at
delivery (years) 0.001 0.177
≤24 107 (9.0) 18 (6.7) 604 (11.9)
25–29 402 (33.9) 73 (27.0) 1437 (28.4)
30–34 424 (35.7) 113 (41.9) 1798 (35.5)
>34 254 (21.4) 66 (24.4) 1221 (24.1)
Mother’s education <0.001 0.133
High school or less 123 (10.6) 36 (13.8) 974 (19.8)
More than high school 1038 (89.4) 225 (86.2) 3954 (80.2)
Maternal
pre-pregnancy body
mass index
0.462 0.278
≤25 776 (66.6) 180 (67.2) 3057 (61.6)
>25 390 (33.4) 88 (32.8) 1905 (38.4)
Smoking during
pregnancy 0.005 0.334
Yes 119 (10.2) 34 (12.6) 552 (11.0)
No 1052 (89.8) 236 (87.4) 4460 (89.0)
Maternal antibiotic use
during pregnancy 0.363 0.605
Yes 289 (24.7) 55 (20.4) 1122 (22.4)
No 882 (75.3) 215 (79.6) 3896 (77.6)
Maternal probiotics
use during pregnancy <0.001 0.317
Yes 91 (7.7) 13 (4.8) 148 (2.9)
No 1096 (92.3) 257 (95.2) 4912 (97.1)
Duration of exclusive
breastfeeding <0.001 <0.001
<3 months or none 887 (74.8) 225 (83.3) 3766 (74.4)
≥3 months 299 (25.2) 45 (16.7) 1293 (25.6)
Age at gluten
introduction 0.313 0.027
<17 weeks 69 (5.9) 11 (4.2) 312 (6.3)
17–26 weeks 425 (36.1) 76 (28.7) 1818 (36.5)
>26 weeks 684 (58.1) 178 (67.2) 2851 (57.2)
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Table 2. Cont.
Source of First Probiotic Exposure
among Probiotics Users during the
First Year of Life a
Non-Users of
Probiotics (n = 5060) p
b p c
Dietary
Supplements
(n = 1187)
Infant Formula
(n = 270)
Child antibiotic use
during the first 12
months
<0.001 0.849
Yes 728 (61.3) 125 (46.3) 2259 (44.6)
No 459 (38.7) 145 (53.7) 2801 (55.4)
Diarrhea during the
first 3 months <0.001 0.268
Yes 115 (9.7) 44 (16.3) 419 (8.3)
No 1072 (90.3) 226 (83.7) 4641 (91.7)
Gastrointestinal
infections during the
first 12 months
<0.001 0.019
Yes 415 (35.0) 92 (34.1) 1496 (29.6)
No 772 (65.0) 178 (65.9) 3564 (70.4)
Common cold during
the first 3 months 0.006 0.055
Yes 677 (57.0) 142 (52.6) 2955 (58.4)
No 510 (43.0) 128 (47.4) 2103 (41.6)
Age at first exposure to
probiotics (weeks) 0.005
Mean (SD) 12 (14) 14 (13)
Median (IQR) 5 (2–17) 10 (2–24)
Duration of probiotic
exposure during the
first year of life (weeks)
0.073
Mean (SD) 30 (18) 25 (18)
Median (IQR) 35 (11–48) 23 (8–44)
a: Three children were exposed to both probiotic dietary supplements and infant formula at the same time and
were not included here. b: p value from the Cochran–Mantel–Haenszel test for the association of characteristics
between probiotics users and non-users during first year of life; analyses adjusted for country. c: p value from the
Cochran–Mantel–Haenszel test (on categorical variables) or the analysis of covariance (on continuous variables) for
the association of characteristics between the sources of first probiotic exposure; analyses adjusted for country. Data
are presented as number (percentage) unless otherwise indicated.
3.3. Risk of CDA and Celiac Disease
There was no difference in the risk of CDA (HR 1.15; 95%CI 0.99, 1.35; p = 0.07) or celiac disease
(HR 1.11; 95%CI 0.86, 1.43; p = 0.43) between probiotics users and non-users during the first year of life
when the models were adjusted for potential confounders: country, sex, HLA-genotype, FDR with
celiac disease, birth year, mode of delivery, mother’s education, duration of exclusive breastfeeding,
and child’s diarrhea during the first 3 months (Table 3). However, probiotic exposure from dietary
supplements alone when compared to no exposure was associated with a slightly increased risk of
CDA when adjusted for the potential confounders (HR 1.18; 95%CI 1.01, 1.40; p = 0.043) (Table 3).
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Table 3. Overall probiotic exposure, timing of first probiotic exposure by source, and the risk of celiac
disease auto-immunity (CDA) and celiac disease.
CDA Celiac Disease
HR (95% CI) a
p
HR (95% CI) b
p
HR (95% CI) a
p
HR (95% CI) b
p
Exposed to
probiotics during
the first year of life:
Yes vs. no 1.11 (0.96, 1.29)0.177
1.15 (0.99, 1.35)
0.073
1.04 (0.82, 1.33)
0.731
1.11 (0.86, 1.43)
0.432
First exposure to
probiotics by
source:
Supplements vs.
none
1.15 (0.98, 1.35)
0.085
1.18 (1.01, 1.40)
0.043
1.03 (0.79, 1.35)
0.804
1.09 (0.83, 1.44)
0.534
Formula vs. none 0.91 (0.64, 1.30)0.616
0.98 (0.69, 1.41)
0.930
1.12 (0.63, 1.98)
0.695
1.20 (0.68, 2.13)
0.537
Age at first
exposure to
probiotics among
users (/week) c,d
1.01 (1.00, 1.02)
0.047
1.01 (1.00, 1.02)
0.210
1.02 (1.01, 1.04)
0.009
1.02 (1.00, 1.03)
0.055
Age at first
exposure to
probiotics among
users whose first
exposure to
probiotics were
from dietary
supplements
(/week) c
1.00 (0.99, 1.01)
0.478
1.00 (0.99, 1.01)
0.618
1.01 (1.00, 1.03)
0.102
1.01 (0.99, 1.03)
0.218
Age at first
exposure to
probiotics among
users whose first
exposure to
probiotics were
from infant
formula (/week) c
1.03 (1.01,1.05)
0.014
1.02 (0.99, 1.05)
0.285
1.04 (1.00, 1.09)
0.044
1.04 (0.99, 1.09)
0.135
a Hazard ratios adjusted for sex, HLA genotype, first-degree relative (FDR) with celiac disease and country. b Hazard
ratios adjusted for sex, HLA genotype, FDR with celiac disease, country, birth year, mode of delivery, mother’s
education, duration of exclusive breastfeeding, and child’s diarrhea during first 3 months. (Birth year, mode of
delivery, mother’s education, duration of exclusive breastfeeding, and child’s diarrhea during first 3 months were
statistically significantly (p-value < 0.05) associated with probiotic exposure during the first year of life, and with
celiac disease autoimmunity (CDA) and/or celiac disease.) c Hazard ratios describe the change in the risk for every
one week delay in the probiotic exposure. d Hazard ratios adjusted additionally for the source of probiotics.
No association was found between the age of the child at the time of initial probiotic exposure
and the risk of the outcomes when adjusting for all the potential confounders (Table 3). However, a
time-to-event analysis with smoothing splines [28,29] showed a slightly increased subsequent risk
of celiac disease when a probiotic dietary supplement was introduced during the first weeks of life
(Figure 1).
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Figure 1. The estimated effects of age at probiotic exposure (by source of probiotics) on the log hazards
of celiac disease autoimmunity (CDA, n = 281) (a,c; nonlinearity: p = 0.054 and p = 0.16, respectively)
and celi c ise se (n = 99) (b,d; nonlinearity: p = 0.16 and p = 0.20, respectively) from time-to-event
analysis with smoothing splines on 1460 subjects who were exposed to probiotics during the first year
of life.
4. Discussion
The present study showed no protective association between overall probiotics use during first
year of life and the risks of CDA or celiac disease in children at increased risk of T1D and celiac disease.
In fact, probiotic exposure from dietary supplements during the first weeks of life was associated
with a small increase in the risk of celiac disease. This finding is in contrast to a recent randomized
double-blinded placebo-controlled study in Sweden in which synergistic effects of probiotics on the
peripheral autoimmune response were observed in genetically predisposed children with CDA who
were receiving two strains of Lactobacillus, as compared to placebo [30]. However, to our knowledge
no other study has investigated the association between probiotic use and celiac disease in children in
a prospective multicenter study like TEDDY.
Probiotic use in the first year of life was positively linked to various infections and antibiotic use
in children. This finding could be interpreted as infectious episodes potentially acting as a confounder
when studying the association between probiotic exposure and the outcomes. However, we did not
find any association between infections or antibiotic use and the risk of CDA or celiac disease in this
study. Probiotics use was associated with shorter exclusive breastfeeding, which could have been
related to earlier introduction of gluten-containing cereals. However, there is no current evidence that
early introduction of gluten could be linked to the risk of celiac disease risk [31,32]. Moreover, the
association between breastfeeding duration and the risk of celiac disease still remains inconclusive [33].
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Administration of antibiotics was not associated with CDA or celiac disease in this study, which is
in line with an earlier report from the TEDDY Study [20] in which antibiotic use between 3 months
and 4 years of age was examined in relation to CDA and celiac disease, adjusting e.g. for probiotic
use during the first 3 months. However, two recent studies suggest that taking antibiotics at an early
age is associated with celiac disease [34,35], although neither of these two studies took potential early
probiotic exposure into account.
Colic usually appears during the first 2–3 weeks of life and a common practice, especially in
Sweden, involves recommending probiotic supplement drops to ease the abdominal discomfort caused
by colic [36]. Unfortunately, colicky events were not recorded in this study and their role as a potential
confounder could not be further evaluated. Nevertheless, the etiology of both colic [37,38] as well as
celiac disease [39] has been associated with dysbiosis in gut microbiota, and both are also associated
with similar health conditions [40,41].
We also speculated whether use of probiotics after the first year of life could be linked to the risk
of CDA or celiac disease. Because yoghurt and other fermented milk products are frequently given to
young children especially after the first year of age, probiotics in the form of dietary supplements or
infant formula could seldom be counted as the first exposure at that age. Food sources of probiotics
(e.g., Lactobacillus species via fermented milk and vegetable products or fortified foods), would then
become more frequent in infant diet, minimizing the importance of dietary supplements as the first
probiotic exposure. Furthermore, given suggestions that gut microbiota is an important part of the
causal pathway of celiac disease, we have to take into consideration that gut microbiota has already
been shaped by solid foods after 1 year of age [42] and the long-term modification of gut microbiota by
introduction of probiotic supplements at that time would probably not be feasible.
The strength of this study is the prospective design including subjects from multiple international
clinical centers, as well as using standardized and validated methods in data collection across the
study centers. The mechanistic actions of probiotic bacteria could be dependent on species and doses
of probiotics, for example. Since this information was not available for this study, it suffers from
limitations despite its large size and prospective design. However, there is currently no definite
consensus by which specific bacteria could be associated with celiac disease [22,43]. The dose of
probiotics could not be studied because of the lack of information on the manufacturing processes and
storage conditions [44] of the large variety of probiotic supplements and infant formulas that were
used by the study participants. There was also limited information about early life events and their
timing due to the retrospective collection of self-reported data at the age of 3 months.
5. Conclusions
This study demonstrated that the overall supplementation of probiotics in infancy was not
associated with celiac disease. However, the finding that first probiotic exposure from dietary
supplements during the first weeks of life was associated with the increased risk of celiac disease
warrants further investigation.
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